关于RhD溶血病的预测和治疗策略主要集中在互补的两个方面——预防和有效处理高危RhD阳性胎儿。在荷兰,通过有效的,自给自足的自愿供者来源的抗-D免疫球蛋白制品工程和广泛的高危孕妇治疗系统,使RhD溶血病的频率降至1％以下。通过冰冻保存合格供者的红细胞至试验完成,显著提高了安全性。此系统直至发现nvCJD之前一直运行很好,人们期待能应用单克隆抗-D制剂。从输血的远景看,对已产生免疫的孕妇的处理,重在通过评价母亲血中抗-D的活力和预测胎儿基因型来预测胎儿RhD溶血病的严重性。通过使用自动分析仪更客观的定量分析可获得更准确的预测结果。生化分析如 Prediction and treatment strategies for RhD hemolytic disease are focused on two complementary aspects - prevention and effective treatment of high-risk RhD-positive fetuses. In the Netherlands, RhD hemolytic disease has been reduced to less than 1% through an anti-D immunoglobulin product from a viable, self-sufficient, voluntary donor and extensive high-risk treatment systems for pregnant women. By freezing the red blood cells of eligible donors to completion of the test, the safety is significantly improved. The system did not work well until nvCJD was found and one would expect to see the use of monoclonal anti-D preparations. From the perspective of blood transfusion, the treatment of pregnant women who have developed immunity focuses on the prediction of the severity of fetal RhD hemolytic disease by evaluating the anti-D activity in the maternal blood and predicting the fetal genotype. More accurate predictions can be obtained by using more objective and quantitative analyzes of automated analyzers. Biochemical analysis such as